Study of ARO-RAGE in Healthy Subjects and Patients With Asthma
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
ARO-RAGE in normal healthy volunteers (NHVs) and in participants with mild to moderate
asthma. In Part 1 of the study, NHVs will receive a single dose of ARO-RAGE or placebo. In
Part 2 of the study, adult participants with asthma will receive 2 doses of ARO-RAGE or
placebo. Additional NHVs may be randomized to receive 1 or 2 doses of ARO-RAGE or placebo at
Sponsor discretion. Dose levels in Part 2 will be determined based on cumulative safety and
pharmacodynamic data from Part 1.